country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-P11917

Copy Link Print Information

LF1

LF1 is a gastrin-releasing peptide receptor (GRPR) antagonist. LF1 can be stably radiolabeled with gallium-⁶⁸, indium-¹¹¹, and lutetium-¹⁷⁷. Radiolabeled LF1 can be used for high-contrast SPECT/CT imaging. LF1 is applicable to prostate cancer-related research.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

分子式: C₈₀H₁₁₉N₁₉O₂₁
分子量:1682.92

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

カスタムペプチド

LF1 構造式

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

One-Stop Platform：From Independent R&D to Pilot-Scale Production

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

^[1]

RDC Peptide

Radionuclide-Drug Conjugates (RDCs) アイソフォーム固有の製品をすべて表示 :

体外実験

OthersAnti-cancer

Others

[¹⁷⁷Lu]Lu-LF1 (1-3 nM) binds to GRPR-expressing prostate cancer PC-3 cells with high affinity and desirable slow dissociation kinetics, with a K_d value of 0.12 nM^[1].

Anti-cancer

⁶⁸/natGa-LF1, ¹⁷⁷/natLu-LF1, and ¹¹¹/natIn-LF1 (1-100 nM; 120 min) bind to GRPr on PC3 cells with high affinity, with K_d values of 16.3 nM, 10.2 nM, and 5.2 nM, respectively^[2].
The combination strategy of Rapamycin (HY-10219) and Lutetium-¹⁷⁷-labelled LF1 (72 h) reduces the viability of PC3 cells more effectively than either agent used alone, with cell viability decreasing to approximately 40% at 72 h^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

human prostate adenocarcinoma PC3 cells
Concentration:

1.85 MBq lutetium-177-labelled LF1
Incubation Time:

72 h
Result:

Resulted in ~70% cell viability at 72 h for lutetium-177-labelled LF1 monotherapy.
Resulted in ~50% cell viability at 72 h for rapamycin monotherapy.
Resulted in ~40% cell viability at 72 h for combination therapy with rapamycin and lutetium-177-labelled LF1.

体内実験

Anti-cancer

[¹⁷⁷Lu]Lu-LF1 (41.2-93.4 MBq; administered in 6 fractions over two 3-day cycles with a 1-week interval between cycles) exhibits a dose-dependent effect in PC-3 tumor-bearing mice, where the fractionated dose of 93.4 MBq induces significant tumor inhibition with a median survival time of 50 days^[1].
Combination therapy with a single dose of [¹⁷⁷Lu]Lu-LF1 (40 MBq) and pretreatment with Everolimus (HY-10218) enhances tumor control in PC-3 tumor-bearing mice and prolongs their median survival to 38 days, whereas a single dose of [¹⁷⁷Lu]Lu-LF1 alone yields no significant benefit^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Balb/C nude (male, 6 weeks old, 20-25 g, subcutaneously implanted with PC-3 cells)^[1]
Dosage:

41.2 MBq (1200 pmol total, 6 fractional doses); 93.4 MBq (2400 pmol total, 6 fractional doses)
Administration:

6 fractional doses over two 3-day periods separated by a 1-week interval
Result:

Showed limited tumor control and reached study end points within 25 days, with a median survival of 16 days (41.2 MBq dose).
Exhibited significant tumor suppression, with tumor volumes remaining under 400 mm³ for at least the first 25 days, and had a median survival of 50 days, with two mice surviving past 104 and 127 days (93.4 MBq dose).
Remained stable across all treated groups (body weight).

化学情報

分子量 1682.92
分子式 C₈₀H₁₁₉N₁₉O₂₁
配列

{AAZTA-Pip-d-Phe}-Gln-Trp-Ala-Val-Gly-His-{Sta}-Leu-NH2
シーケンスの短縮

{AAZTA-Pip-d-Phe}-QWAVGH-{Sta}-L-NH2
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

取扱説明書 (2659 KB)

参考文献

[1]. Kumar N, et al. Preclinical Evaluation of a Lu-Labeled Gastrin-Releasing Peptide Receptor Antagonist and Prostate Cancer Treatment with Monotherapy and in Combination with Everolimus. ACS pharmacology & translational science. 2026 Jan 09;9(1):59-68.

[2]. Hofstetter M, et al. Effect of the versatile bifunctional chelator AAZTA on the radiometal labelling properties and the in vitro performance of a gastrin releasing peptide receptor antagonist. EJNMMI radiopharmacy and chemistry. 2020 Nov 30;5(1):29.

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ

Amount: USD 0.00

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
純度とドキュメンテーション
参考文献

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

LF1

Radionuclide-Drug Conjugates (RDCs) アイソフォーム固有の製品をすべて表示